-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
As described by Guyatt et al.
, doctors face the paradox of evidence-based medicine every day while trying to determine the best treatment for a single patient
.
In 19861, doctors could not trust their own informal treatment trials.
As described by Guyatt et al.
As an alternative, the N-of-1 trial (ie, single-patient crossover trial) uses the key methodological elements of parallel group trials to ensure scientific rigor, while generating clinically relevant treatment results tailored to the patients involved
Recently, the results of a series of N-of-1 trials have been aggregated as a substitute for randomized controlled trials)
v
Starting from December 1, 2019, researchers will search for reports on the N-of-1 trial of neurological diseases on PubMed, MEDLINE and Embase
.
Extract basic trial information about design, disease, intervention, analysis, and treatment success
Starting from December 1, 2019, researchers will search for reports on the N-of-1 trial of neurological diseases on PubMed, MEDLINE and Embase
- A total of 40 reports on N-of-1 trials for neurological diseases were searched (19 separate N-of-1 trials, 21 N-of-1 series trials)
The N-of-1 N-of-1 N-of-1 test has been reported in many neurological diseases, not only in chronic stable diseases, but also in progressive or acute diseases with stable symptoms
Source: Pallud J, Huberfeld G, Dezamis E, et al.
Effect of Levetiracetam Use Duration on Overall Survival of Isocitrate Dehydrogenase Wildtype Glioblastoma in Adults: An Observational Study [published online ahead of print, 2021 Oct 21].
Neurology.
2021; 10.
1212/WNL.
0000000000013005.
doi:10.
1212/WNL.
0000000000013005 Pallud J, Huberfeld G, Dezamis E, et al.
Effect of Levetiracetam Use Duration on Overall Survival of Isocitrate Dehydrogenase Wildtype Glioblastoma in Adults: An Observational Study [published online ahead of print .
, 2021 Oct 21] Neurology 2021 ; 10.
1212 / WNL.
0000000000013005 doi:.
.
10.
1212 / WNL.
0000000000013005 in this message
